Phase III study of Sufentanil NanoTab PCA System (AcelRx Pharmaceuticals) shows superiority to morphine for Pain relief

Clinical results from a Phase III trial of Sufentanil NanoTab PCA System, from AcelRx Pharmaceuticals, for the treatment of moderate-to-severe Acute Pain in the hospital setting demonstrate that sufentanil delivered via the NanoTab System has a significantly greater pain intensity reduction in the first four hours after treatment than IV PCA morphine (p<0.01).>

In addition, there were fewer patients throughout the study that experienced oxygen desaturation events below 95% in the Sufentanil NanoTab PCA System group than in the IV PCA morphine group (p=0.028). Oxygen saturation is a measure of a patient's respiratory function and can be affected negatively by opioids. Data was presented in five posters at the American Society of Regional Anesthesia and Pain Medicine (ASRA) spring meeting. Sufentanil NanoTab PCA System remains on track for a Q3 2013 NDA submission.